Table 2.
Group | n | BAC mmol/L |
ALT IU |
MDA nmol/mg |
GSH μmol/mg |
|
---|---|---|---|---|---|---|
MALE (24 Wks) |
Control (C) | 9 | 1.3±0.1* | 11.3±0.9* | 1.64±0.16* | 5.74±0.16* |
EtOH (E) | 9 | 14.3±1.2 | 29.1±3.9 | 7.70±0.75 | 4.58±0.24 | |
DEN (D) | 9 | 1.2±0.1* | 45.5±4.4* | 6.87±0.67§ | 4.02±0.04§ | |
DEN+EtOH (D+E) | 14 | 13.3±1.1# | 60.7±7.2*# | 8.81±0.49*# | 2.98±0.11*#§ | |
FEMAL E (24 Wks) |
Control (C) | 10 | 1.3±0.1* | 11.2±1.1* | 2.10±0.27* | 6.06±0.15* |
EtOH (E) | 10 | 10.4±1.0 | 35.3±3.2 | 8.12±0.72 | 5.15±0.13 | |
DEN (D) | 9 | 1.3±0.1* | 37.3±4.0 | 5.43±0.83* | 4.99±0.08 | |
DEN+EtOH (D+E) | 14 | 12.2±1.0# | 57.0±5.2*# | 8.51±0.61# | 3.87±0.18*# | |
Group | n | BAC mg/dL |
ALT IU |
MDA nmol/mg |
GSH μmol/mg |
|
MALE (48 Wks) |
Control (C) | 9 | 1.5±0.1* | 14.7±0. 9* | 2.77±0.09* | 5.86±0.14* |
EtOH (E) | 9 | 11.5±0.9 | 53.5±7.5 | 6.85±0.92§ | 4.34±0.36 | |
DEN (D) | 8 | 3.0±0.6* | 116.1±16.1*§ | 8.16±0.53* | 4.09±0.14§ | |
DEN+EtOH (D+E) | 14 | 14.2±0.8# | 131.3±17.3* | 14.35±0.76*#§ | 2.43±0.11*#§ | |
FEMAL E (48 Wks) |
Control (C) | 10 | 1.3±0.2* | 15.3±2.2* | 2.19±0.31* | 5.97±0.14* |
EtOH (E) | 10 | 12.5±0.9 | 45.2±6.8§ | 5.26±0.79 | 4.91±0.08 | |
DEN (D) | 9 | 2.5±0.2* | 124.6±19.6* | 7.79±0.81* | 4.90±0.08 | |
DEN+EtOH (D+E) | 14 | 13.1±0.8# | 107.0±13.9*# | 11.52±1.14*# | 3.06±0.15*# |
p<0.05 versus respective male or female E mice,
p<0.05 D+E mice versus respective male or female D mice,
p<0.05 male versus female within same treatment group/time points.